Evidence map›Paper›PMID 31614958›Full record

ReviewCells2019

Nuclear-cytoplasmic Shuttling in Chronic Myeloid Leukemia: Implications in Leukemia Maintenance and Therapy.

Giovanna Carrà, Isabella Russo, Angelo Guerrasio, Alessandro Morotti

Abstract readReview
In one paragraph

Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giovanna CarràDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano (Turin), Italy. giovanna.carra@unito.it.ORCID 0000-0002-6263-6800
Isabella RussoDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano (Turin), Italy. isabella.russo@unito.it.ORCID 0000-0002-2921-1763
Angelo GuerrasioDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano (Turin), Italy. angelo.guerrasio@unito.it.
Alessandro MorottiDepartment of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano (Turin), Italy. alessandro.morotti@unito.it.ORCID 0000-0002-8407-2903

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear-cytoplasmic shuttling is a highly regulated and complex process, which involves both proteins and nucleic acids. Changes in cellular compartmentalization of various proteins, including oncogenes and tumor suppressors, affect cellular behavior, promoting or inhibiting proliferation, apoptosis and sensitivity to therapies. In this review, we will recapitulate the role of various shuttling components in Chronic Myeloid Leukemia and we will provide insights on the potential role of shuttling proteins as therapeutic targets.

Indexed as

ApoptosisCell NucleusCytoplasmCytosolExportin 1 ProteinHumansHydrazinesKaryopherinsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNuclear Export SignalsNuclear Localization SignalsReceptors, Cytoplasmic and NuclearTriazolesExportin 1 ProteinHydrazinesKaryopherinsNuclear Export SignalsNuclear Localization SignalsReceptors, Cytoplasmic and NuclearselinexorTriazolesBCR-ABLchronic myeloid leukemiamiRNAnuclear-cytoplasmic shuttlingp53PTEN

Identifiers

PMID31614958
PMCPMC6830087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.